About pharming group nv - PHGUF
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
PHGUF At a Glance
Pharming Group NV
Vondellaan 47
Leiden, Zuid-Holland 2332 AA
| Phone | 31-71-524-74-00 | Revenue | 297.20M | |
| Industry | Pharmaceuticals: Major | Net Income | -11,841,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 21.15% | |
| Fiscal Year-end | 12 / 2025 | Employees | N/A | |
| View SEC Filings |
PHGUF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.164 |
| Price to Book Ratio | 2.948 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 79.634 |
| Enterprise Value to Sales | 1.977 |
| Total Debt to Enterprise Value | 0.191 |
PHGUF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 5.924 |
| Total Asset Turnover | 0.674 |
PHGUF Liquidity
| Current Ratio | 3.773 |
| Quick Ratio | 3.018 |
| Cash Ratio | 2.275 |
PHGUF Profitability
| Gross Margin | 84.374 |
| Operating Margin | -1.233 |
| Pretax Margin | -2.265 |
| Net Margin | -3.984 |
| Return on Assets | -2.684 |
| Return on Equity | -5.384 |
| Return on Total Capital | -3.552 |
| Return on Invested Capital | -3.33 |
PHGUF Capital Structure
| Total Debt to Total Equity | 50.806 |
| Total Debt to Total Capital | 33.69 |
| Total Debt to Total Assets | 27.303 |
| Long-Term Debt to Equity | 47.553 |
| Long-Term Debt to Total Capital | 31.533 |